WNT16 and osteoporosis: WNT16 is one such ligand that can influence the activity of canonical and noncanonical Wnt pathways.(9, 10) Recently, WNT16 has emerged as a regulator of cortical bone thickness and BMD, with mutations in WNT16 linked to osteoporosis susceptibility in human genome wide‐association studies (GWASs).(11, 12) Furthermore, a meta‐analysis of GWASs in women aged 20 to 45 years also associated WNT16 with lumbar‐spine BMD, indicating that WNT16 may influence BMD throughout life, not only in postmenopausal populations.(13)